Huntingtons Disease
BMJ 341:34-40, Novak,M.J. &Tabrizi,S.J., 2010
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Predictive Testing for Huntington's Disease: the Calm After the Storm
Lancet 356:1944-1945, Hayden,M.R., 2000
Longitudinal Change in Basal Ganglia Volume in Patients with Huntington's Disease
Neurol 48:394-399, Aylward,E.H.,et al, 1997
CAG Repeat Number Governs the Development Rate of Pathology in Huntington's Disease
Ann Neurol 41:689-692, Penney,J.B.,et al, 1997
Genetic Testing of Children at Risk for Huntington's Disease
Neurol 49:1048-1053, Nance,M.A.,et al, 1997
Juvenile Huntington Disease:CT and MR Features
AJNR 16:1405-1412, Ho,V.B.,et al, 1995
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
Molecular Genetics in Neurology
Ann Neurol 34:757-773, Martin,J.B., 1993
Serial Changes of Cerebral Glucose Metab & Caudate Size in Persons at Risk for Huntington's Dis
Arch Neurol 49:1161-1167, Grafton,S.T.,et al, 1992
Clinical-Pathologic Correlation in Huntington's Disease:A Neuropsychological and Computed Tomography Study
Neurol 39:796-801, Bamford,K.A.,et al, 1989
Huntington's Disease Mortality in the United States
Neurol 38:769-772, Lanska,D.J.,et al, 1988
Adoption and Genetic Prediction for Huntington's Disease
Lancet 2:1069-1070, Morris,M.,et al, 1988
Normal Caudate Glucose Metabolism in Persons at Risk for Huntington's Disease
Arch Neurol 44:254-257, Young,A.B.,et al, 1987
Reduced Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease
NEJM 316:357-362, Mazziotta,J.C.,et al, 1987
The Combined Use of Positron Emission Tomography & DNA Polymorphisms for Preclinical Detection of Huntington's Disease
Neurol 37:1441-1447, Hayden,M.R.,et al, 1987
Positron Emission Tomography in the Early Diagnosis of Huntington's Disease
Neurol 36:888-894, Hayden,M.R.,et al, 1986
Huntington's Disease, Pathogenesis & Management
NEJM 315:1267-1276, Martin,J.B.&Gusella,J.F., 1986
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
PET Scan Investigations of Huntington's Disease:Cerebral Metabolic Corr. of Neuro & Funct Decline
Ann Neurol 20:296-303, Young,A.B.,et al, 1986
Parental Transmission in Huntington's Disease
Lancet 1:1100-1102, Went,L.N.,et al, 1984
Increased Rate of Suicide Among Patients with Huntington's Disease
JNNP 47:1283-1287, Schoenfeld,M.,et al, 1984
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
Levels of y-Aminobutyric Acid in Cerebrospinal Fluid in Various Neurologic Disorders
Arch Neurol 37:352-355, Manyam,N.V.B.,et al, 1980
Juvenile Huntington Chorea:Clinical, Ultrastructural, & Biochemical Studies
Neurol 28:23, Goebel,H.H.,et al, 1978
Bicaudate Index in Computerized Tomography of Huntington Disease & Cerebral atrophy
Neurol 28:1196-1200, Barr,A.N.,et al, 1978
Identification of GABA in Human CSF by Gas Liquid Chromatography & Mass Spectrometry
NEJM 296:692, Huizinga,J.D.,et al, 1977
Clinical Neuropathological Conference
(Ed) , Dis Ner Sys 34:124, 1973, Pick's Disease., Aronson,S.&Aronson,B., 1973
Huntington's Disease in Children
Neurol 23:561, Byers,R.,et al, 1973
Clinical Diagnosis of the Dyskinesias
Med Clin of North Am 56:1321, Duvoisin,R., 1972
Diseases of the Extrapyramidal System
Disease-a-month-Jan 1970., Klawans,H.,et al, 1970
Diseases of the Basal Ganglia-Their Relation to Disorders of Movement
Lancet 1099, 1960, Nov., Denny-Brown,D., 1960
Huntington Disease: Clinical Features and Diagnosis
UptoDate Dec 2017, Oksana Suchowersky, 2017
On-Road Driving Impairments in Huntingtons Disease
Neurol 82:956-962, Devos, H.,et al, 2014
Head Drop in Huntington Disease: Insights into the Pathophysiology
Neurol 81:769-770, Morgante, F.,et al, 2013
CAG Repeat Expansion in Huntington Disease Determines Age at Onset in a Fully Dominant Fashion
Neurol 78:690-695, Lee,J.M.,et al, 2012
Evidence-Based Guideline: Pharmacologic Treatment of Chorea in Huntington Disease
Neurol 79:597-603, Armstrong, M.J. & Miyasaki, J.M., 2012
Predictors of Diagnosis in Huntington Disease
Neurol 68:1710-1717, Langbehn,D.R.,et al, 2007
Neural Transplantation in Huntington Disease: Long-Term Grafts in Two Patients
Neurol 68:2093-2098, Keene,C.D.,et al, 2007
Psychiatric Disorders in Preclinical Huntingtons Disease
JNNP 78:939-943, Julien,C.L.,et al, 2007
Tetrabenazine as Antichorea Therapy in Huntington Disease, A Randomized Controlled Trial
Neurol 66:366-372, Huntington Study Group, 2006
The Association of CAG Repeat Length with Clinical Progression in Huntington Disease
Neurol 66:1016-1020, Rosenblatt,A.,et al, 2006
Saccades in Presymptomatic and Early Stages of Huntington Disease
Neurol 67:394-399, Blekher,T.,et al, 2006
Identification of an Oculomotor biomarker of Preclinical Huntington Disease
Neurol 67:485-487, Golding,C.V.P.,et al, 2006
Effect of Donepezil on Motor and Cognitive Function in Huntington Disease
Neurol 67:1268-1271, Cubo,E.,et al, 2006
Functional Brain Changes in Presymptomatic Hunington's Disease
Ann Neurol 55:879-883, Reading,S.A.,et al, 2004
Prenatal Diagnosis Requests for Huntington's Disease when the Father is at Risk, and Does Not Want to Know His Genetic Status: Clinical, Legal, and Ethical Viewpoints
BMJ 326:331-333, Tassicker,R.,et al, 2003